No Data
No Data
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$153.26K in Common Stock
$Rhythm Pharmaceuticals(RYTM.US)$ Officer Shulman Joseph sold 3,984 shares of common stock on May 9, 2024 at an average price of $38.4685 for a total value of $153.26K.Source: Announcement What is sta
Press Release: Rhythm Pharmaceuticals Announces New Employment Inducement Grants
Rhythm Pharmaceuticals Announces New Employment Inducement Grants BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a commercial-stage biopharmaceutical company fo
Anti-Obesity Drugs Global Strategic Business Report 2024-2030 Featuring F. Hoffmann-La Roche, GlaxoSmithKline, Eisai, Novo Nordisk, Rhythm Pharmaceuticals, and VIVUS - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--The "Anti-Obesity Drugs - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering.Global Anti-Obesity Drugs Market to Reach $4.8 Billion b
Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rhythm Pharmaceuticals Is Maintained at Buy by Canaccord Genuity
Rhythm Pharmaceuticals Price Target Cut to $79.00/Share From $80.00 by Canaccord Genuity
Rhythm Pharmaceuticals Price Target Cut to $79.00/Share From $80.00 by Canaccord Genuity
Canaccord Genuity Maintains Buy on Rhythm Pharmaceuticals, Lowers Price Target to $79
Canaccord Genuity analyst Whitney Ijem maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and lowers the price target from $80 to $79.